On 10 December, Alzheimer Europe (AE) hosted a Company Round Table meeting in Brussels. The meeting was a hybrid event, with many participants attending in person and some joining remotely. The meeting brought together company representatives from AVP, Alzheon, Biogen, Danone (Nutricia), Eisai, Johnson & Johnson and Roche, alongside AE staff and members from national Alzheimer organisations. During the meeting, four speakers provided updates on recent policy and research developments.
First, Cindy Birck, AE Project Officer, gave an update on our Clinical Trials Watch, an online database providing accessible and up-to-date information on clinical trials that are investigating drugs for Alzheimer’s disease and/or dementia. Next, Owen Miller, AE Project Officer, shared some updates on EU policy developments, European Parliament elections and AE European Parliament election campaign, noting that 83 organisations signed the Helsinki Manifesto.
The next presentation was given by Angela Bradshaw, AE Director for Research, addressing advancements in anti-amyloid treatments, particularly focusing on the regulatory processes for lecanemab and donanemab in Europe. The meeting was moderated by Jean Georges, AE Executive Director who also gave the final presentation of the meeting, informing participants about Alzheimer Europe’s activities in 2024. Looking ahead, he also shared plans for 2025, highlighting upcoming meetings aligned with AE’s strategic objectives.
We would like to thank our sponsors and members for participating in this meeting and we look forward to welcoming them to the next Company Round Table meeting, which will take place online, on 1 April 2025.
